Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Q&A: Vectura's Leaders Explain Synergies And Priorities For Merged Company

Executive Summary

Vectura's CEO James Ward-Lilley and incoming CFO from Skyepharma, Andrew Derodra, sat down with Scrip and explained where they see the excitement, synchronization and R&D fusion for the larger company.

You may also be interested in...

Sterna Sitting Pretty As Inflammatory Pipeline Shows Promise

In an interview with Scrip, Sterna Biologicals CEO Christian Pangratz says that the small German company has a number of options available to advance its Phase II projects in asthma, COPD, ulcerative colitis and atopic dermatitis.

Vectura CFO Sanguine Despite Flutiform Phase III COPD Trial Miss

Respiratory specialist Vectura has shrugged off disappointing Phase III results of Flutiform in COPD that could preclude the therapy’s use in that indication, saying that all hope is not yet lost and that the impact will be marginal in any case given Flutiform’s rising sales in treating asthma.

Welcome To Alexion 2.0

In an exclusive interview, Alexion R&D head John Orloff takes In Vivo on a tour around the company’s rejuvenated pipeline and explains how the business is innovating to pre-empt the Soliris-shaped hole in its balance sheet.





Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts